Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazil launches massive cancer Gene-Mapping project in public hospitals

NCT ID NCT05306600

Knowledge-focused Sponsor: Hospital Moinhos de Vento Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and ancestry influence cancer, paving the way for more personalized treatments in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

882 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Institutions from each region that serve Public Health System patients and have high complexity oncology care centers will be included in both Arms to provide a sample that represents the heterogeneity of the Brazilian population. Institutions previously evaluated and validated by the Brazilian Ministry of Health will be selected after completing a feasibility questionnaire. It is estimated that 25 to 30 institutions will be included (at least one from each region) in Arm 1. For Arm 2, 10 centers will be selected from among previously approved institutions.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for breast cancer patients (Arm 1): * Women aged ≥ 18 years; * Brazilian nationality; * After review at the Hospital Moinhos de Vento, confirmed histological diagnosis of breast carcinoma with overexpression of HER2 (classified by immunohistochemistry as 3+ or 2+ with positive in-situ hybridization) or triple-negative (estrogen and progesterone receptors \<1% and no overexpression of HER2); * Clinical stage II or III for HER2-positive and I, II and III for triple-negative patients - American Joint Committee on Cancer (AJCC) 8th edition; * HER2- positive patients: must undergo neoadjuvant chemotherapy plus trastuzumab in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel), combined with trastuzumab, or a non-anthracycline option consisting of taxane (docetaxel or paclitaxel) combined with carboplatin and trastuzumab; * Triple-negative patients: must undergo neoadjuvant chemotherapy without immunotherapy in the following regimens: anthracycline (doxorubicin or epirubicin) followed by taxane (docetaxel or paclitaxel) with/ without platins (carboplatin ou cisplatin) or a regimen without anthracycline (taxane with/without platins) * Patients must provide written informed consent prior to inclusion Inclusion criteria for patients with prostate cancer (Arm 2): * Men aged ≥ 18 years; * Confirmed histological diagnosis of prostate adenocarcinoma; * AJCC 8th edition clinical stage IV; * Patients must provide written informed consent. Exclusion criteria for Arms 1 and 2: * No available paraffin-embedded tumor tissue for genomic analysis; * Inability to collect blood for genomic evaluation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma prostate adenocarcinoma prostate cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Prostate cancer

Contacts and locations

Locations

  • Fundação Centro de Controle de Oncologia do Estado do Amazonas

    Manaus, Amazonas, Brazil

  • Grupo Hospitalar Conceição

    Porto Alegre, 91350-200, Brazil

  • Hospital Araújo Jorge

    Goiânia, 74605-070, Brazil

  • Hospital Calixto Midlej Filho/ Santa Casa de Itabuna

    Itabuna, Estado de Bahia, Brazil

  • Hospital Escola da Universidade Federal de Pelotas

    Pelotas, Rio Grande do Sul, Brazil

  • Hospital Fêmina

    Porto Alegre, Brazil

  • Hospital Ophir Loyola

    Belém, Pará, Brazil

  • Hospital Santa Rita de Cássia - AFECC

    Vitória, Espírito Santo, Brazil

  • Hospital São Camilo

    São Paulo, 04015-070, Brazil

  • Hospital São Lucas da PUCRS

    Porto Alegre, 90610-001, Brazil

  • Hospital Universitário Cassiano Antônio de Moraes

    Vitória, 29043-260, Brazil

  • Hospital Universitário Getúlio Vargas

    Manaus, Amazonas, Brazil

  • Hospital Universitário João de Barros Barreto

    Belém, Pará, Brazil

  • Hospital Universitário Maria Aparecida Pedrossian

    Campo Grande, 79080-190, Brazil

  • Hospital Universitário de Brasília

    Brasília, Federal District, Brazil

  • Hospital da Santa Casa de Misericórdia

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital das Clínicas

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, 90035-903, Brazil

  • Hospital do Amor

    Barretos, São Paulo, Brazil

  • Hospital do Câncer de Londrina

    Londrina, Paraná, Brazil

  • Hospital do Câncer do Maranhão

    São Luís, Maranhão, Brazil

  • Hospital do Câncer/União Oeste Paranaense de Estudo e Combate ao Câncer

    Cascavel, Paraná, 85.806-300, Brazil

  • Instituto Nacional do Câncer (INCA)

    Rio de Janeiro, Brazil

  • Liga Norte Riograndense Contra o Câncer

    Natal, Rio Grande do Norte, Brazil

  • Serviço de Assistência Médica e Urgência S.A. SAMUR

    Vitória da Conquista, Estado de Bahia, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.